How Can We Manage Risks and Ensure Compliance in Bioanalytical Testing?
Benefit from the expertise of a renowned bioanalytical laboratory experienced in addressing challenges related to gene therapy and regulatory toxicology. This whitepaper empowers drug developers to mitigate risks in preclinical drug development through the utilization of liquid chromatography mass spectrometry (LCMS) methods that adhere to Good Laboratory Practices Toxicology (GLP tox) standards. Download to ensure preparedness for clinical trials by improving precision to overcome matrix effects across various animal species.
- Explore high-resolution mass spectrometry for DART and IND studies.
- Minimize sources of variability to overcome matrix effects.
- Optimize calibration accuracy to enhance drug safety and efficacy.
- Address challenges unique to biotherapeutic development.
- Maximize resources by predicting toxicity earlier in development.